Tocilizumab cuts mortality risk in severely ill COVID-19 patients finds new trial conducted in India
(University of Bristol) Tocilizumab, an anti-inflammatory drug used to treat rheumatoid arthritis, improves outcomes in severely ill COVID-19 patients, finds the results of a new trial conducted in hospitals across India -- one of the world's most ethnically diverse countries.
Source: EurekAlert! - Medicine and Health - Category: International Medicine & Public Health Source Type: news
More News: Actemra | Arthritis | COVID-19 | Hospitals | India Health | International Medicine & Public Health | Rheumatoid Arthritis | Rheumatology